Sweet Broomweed

Generic name: Scoparia Dulcis L.
Brand names: Escobilla, Sweet Broomweed, Typycha Kuratu, Vassourinha

Usage of Sweet Broomweed

A variety of applications have been suggested for S. dulcis extracts including antimalarial, antiulcer, antipyretic, and aphrodisiac activities, as well as cytotoxicity activity against cancer cells, and reviews of the topic have been published.(Hayashi 2011, Pamunuwa 2016)

Analgesic and anti-inflammatory activity

Animal data

The diterpene scoparinol demonstrated significant analgesic (P<0.001) and anti-inflammatory activity (P<0.01) in animals.(Ahmed 2001)

Pretreatment of ethanolic extracts of S. dulcis (0.5 g/kg) reduced acetic acid-induced writhing in mice 47%. The extract (0.5 and 1 g/kg) also inhibited paw edema in rats induced by carrageenan 46% and 58%, respectively, after 2 hours. The triterpene glutinol (30 mg/kg) reduced writhing in mice induced by acetic acid 40% and paw edema in rats induced by carrageenan 73%, indicating that the analgesic activity of S. dulcis is most likely related to the anti-inflammatory activity of glutinol.(Freire 1991)

Anticancer activity

In vitro and in vivo

Scopadulcic acid B inhibited the effects of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). Scopadulcic acid B also inhibited TPA-enhanced phospholipid synthesis in cultured cells and inhibited the effect of TPA on skin tumor formation in mice initiated with 7,12-dimethylbenz[a]anthracene.(Nishino 1993)

Four new labdane-derived diterpenes, isolated from the aerial parts of S. dulcis, were cytotoxic against the following 6 human stomach cancer cell lines: SCL, SCL-6, SCL-37′6, SCL-9, Kato-3, and NUGC-4. Vinblastine sulfate and mitomycin C were used as positive controls.(Ahsan 2003)

Scopadulcic acid C, another diterpene, enhanced the antitumor efficacy of acyclovir and ganciclovir in a HSV-TK gene therapy system. The synergistic activity was caused by the activation of viral thymidine kinase.(Nkembo 2005, Nakagiri 2005)

Antimalarial activity

In vitro

The diterpenoid scopadulcic acid A has activity against various Plasmodium falciparum isolates with an IC50 of 27 mcM against the D6 clone (African Sierra isolate) and an IC50 of 19 mcM against the W2 clone (Indochina isolate). The IC50 against the multidrug-resistant TM91C235 (Thailand) isolate was 23 mcM. For comparison, IC50 values for chloroquine were 9.3, 266, and 24 nM against D6, W2, and TM91C235. The IC50 values for mefloquine were 36, 4.8, and 59 nM against D6, W2, and TM91C235.(Riel 2002)

Antiviral activity

In vitro

The diterpenoid scopadulcic acid B inhibited viral replication of herpes simplex virus type 1 in a hamster test model. The mechanism of action is unknown but does not involve a direct virucidal effect or inhibition of virus attachment. Topical application or intraperitoneal injections at 100 and 200 mg/kg/day prolonged the development of herpetic lesions and survival time when treatment was initiated immediately after virus inoculation.(Hayashi 1988, Hayashi 1990)

Diabetes

Animal and in vitro data

The flavone glycosides, including isovitexin, inhibit activity against β-glucuronidase.(Hayashi 1992, Kawasaki 1988) Treatment with aqueous S. dulcis extracts and glibenclamide significantly improved specific insulin binding in streptozotocin-induced male Wistar rats. The number of insulin receptors and affinity binding (P<0.001) was reduced to normal nondiabetic levels. Overall, the results suggest an increase in total endoplasmic reticulum (ER) membrane insulin binding sites with a concomitant increase in plasma insulin in rats treated with aqueous S. dulcis extract or glibenclamide. The mean specific binding of insulin to ER was lower in diabetic control rats (55 +/- 2.8%) than in aqueous S. dulcis–treated (70 +/- 3.5%) and glibenclamide-treated (65 +/- 3.3%) diabetic rats, resulting in a decrease in plasma insulin.(Pari 2004)

An aqueous extract of S. dulcis plant was administered orally for 6 weeks to streptozotocin diabetic rats. The level of plasma insulin was decreased, and the levels of blood glucose and plasma glycoproteins were increased in diabetic control rats. The diabetic control rats also had a decrease in the level of sialic acid and elevated levels of hexose, hexosamine, and fucose in the liver and kidney. After oral administration of S. dulcis plant extracts, the controls had decreased levels of blood glucose and plasma glycoproteins. Plasma insulin and tissue sialic acid levels were increased, and hexose, hexosamine, and fucose tissue levels were near normal in controls.(Latha 2005)

Similar animal experiments using aqueous S. dulcis extracts of 200 mg/kg/day resulted in antihyperglycemic effects, including increased hemoglobin levels, decreases in hemoglobin A1c levels, increased sorbitol dehydrogenase, lipid peroxidation, and antioxidant activity in the liver of diabetic rats.(Latha 2004)

Several animal studies documented the antioxidant activity of the plant, particularly against lipidperoxidation-induced membrane damage. A typical dosage regimen of an aqueous S. dulcis extract of 200 mg/kg/day resulted in an increase in the activities of pancreatic superoxide dismutase, catalase, glutathione peroxidase, and glutathione-S-transferase, and reduced glutathione.(Latha 2004, Pari 2004, Pari 2005)

Clinical data

A small (N=35) randomized crossover clinical trial with type 2 diabetic patients evaluated the effect of porridge made with S. dulcis leaf extract, and reported decreased fasting blood glucose and HbA1c at the 3 month evaluation point. No effect on cholesterol indices was found.(Senadheera 2015)

GI activity

The mechanism of action of the diterpenoid scopadulcic acid B and its debenzoyl derivative, diacetyl scopadol (DAS) involves inhibition of K+-dependent dephosphorylation of proton pumping for gastric acid secretion.(Hayashi 1990)

In vitro

Scopadulcic acid B and its debenzoyl derivative, DAS, dose-dependently and specifically inhibited the ATP hydrolysis by gastric H+K-ATPase (proton pump for gastric acid secretion) but not Na+K+-ATPase activity. With respect to activating the cation K+, scopadulcic acid B is considered a mixed inhibitor, while DAS is considered an uncompetitive inhibitor. This action differs from the irreversible inhibitor omeprazole. Detailed mechanisms and specific inhibition effects in the catalytic reaction of scopadulcic acid B and DAS are provided in the study.(Asano 1990, Hayashi 1991)

Neurotrophic activity

Animal and in vitro data

The acetylated flavone glycosides from S. dulcis have NGF-potentiating activity, which may be useful in treating neurological disorders.

In control experiments, following incubation, the percentages of neurite-bearing cells in PC12D cells were 27% with 2 ng/mL NGF and 71% with 30 ng/mL NGF after 48 hours. After incubation with the glycosides from S. dulcis, neurite outgrowth in PC12D cells was increased by an additional 16% and 15%, respectively.(Li 2004a, Li 2004b)

Oral administration of S. dulcis 200 mg/kg/day for 33 days prior to exposure to noise stress enabled rats to maintain normal corticosterone levels as well as immune biomarkers that suggest beneficial adaptogenic effects via the neuroimmune system.(Sundareswaran 2017)

Other uses

In an animal study, an aqueous fraction of S. dulcis revealed the presence of 2 catecholamines, noradrenaline and adrenaline, that may account for the hypertensive and inotropic effects after parenteral administration.(Freire 1996)

A significant effect on onset and duration of sleep (P<0.05) was caused by scoparinol on pentobarbital-induced sedation in animals. In another animal study, sleeping time induced by sodium pentobarbital 50 mg/kg was prolonged 2-fold in mice pretreated with 0.5 g/kg of an ethanolic extract of S. dulcis. Scoparinol has a diuretic action in animals as demonstrated by the measurement of urine volume after administration.(Ahmed 2001, Freire 1991)

Sweet Broomweed side effects

The plant species is associated with sympathomimetic effects.

Before taking Sweet Broomweed

Avoid use because of the lack of clinical data regarding safety and efficacy in pregnancy and lactation. An aqueous fraction of S. dulcis contained catecholamines, noradrenaline and adrenaline, that may account for the sympathomimetic effects of the plant.(Freire 1996)

How to use Sweet Broomweed

Clinical trials are lacking upon which to provide guidance. Commercially, S. dulcis is often sold in combination with other herbs. It is available in tablet, capsule, and powder doseforms.

Warnings

None suggested because of the lack of clinical data.

What other drugs will affect Sweet Broomweed

Scopadulcic acid C, a diterpene from S. dulcis, enhanced the antitumor efficacy of acyclovir and ganciclovir in a HSV-TK gene therapy system. Patients diagnosed with cardiovascular disease should avoid use because the aqueous fraction of S. dulcis revealed the presence of 2 catecholamines that may account for its hypertensive and inotropic effects. Avoid use or monitor therapy if using proton pump inhibitors (omeprazole [Prilosec]) or antacids because of the potential drug-drug interaction if also consuming any of the commercially available products containing S. dulcis. Avoid use or monitor therapy if diagnosed with diabetes and/or using insulin products.(Freire 1996, Nakagiri 2005, Nkembo 2005)

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords